PASG.US Passage Bio Inc

Healthcare Biotechnology USA Stocks
4.13 USD
Close of Nov 17, 2026
3.29 20.00
Market cap
USD 13.3M
P/E
-
P/B
273.51x
ROE
-53,597.3%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is PASG.US undervalued?

Graham number

The Graham number of Passage Bio Inc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Passage Bio Inc fundamental analysis

No fundamental analysis for Passage Bio Inc yet.

Passage Bio Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Passage Bio Inc

Passage Bio, Inc., a genetic medicines company, develops gene therapies for central nervous system diseases. It develops PBFT02, a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD caused by progranulin deficiency; PBGM01, a functional GLB1 gene encoding ß-galactosidase for infantile GM1; and PBKR03, for the treatment of Krabbe disease. The company develops PBML04 for the treatment of metachromatic leukodystrophy; PBAL05 for the treatmen…

Full company profile